JP2019535306A - Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体 - Google Patents

Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体 Download PDF

Info

Publication number
JP2019535306A
JP2019535306A JP2019542804A JP2019542804A JP2019535306A JP 2019535306 A JP2019535306 A JP 2019535306A JP 2019542804 A JP2019542804 A JP 2019542804A JP 2019542804 A JP2019542804 A JP 2019542804A JP 2019535306 A JP2019535306 A JP 2019535306A
Authority
JP
Japan
Prior art keywords
antibody
seq
monoclonal antibody
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535306A5 (https=
Inventor
ベンスッサン，アルマンド
ロバート，ブルーノ
マルチノ，ピエル
チェントウフ，ミリアム
マリー−カーディン，アン
ガスチニアニ，ジェローム
Original Assignee
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル）
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）
ユニバーシティ パリ ディドロ−パリ ７
ユニバーシティ パリ ディドロ−パリ ７
ユニヴェルシテ ドゥ モンペリエ
ユニヴェルシテ ドゥ モンペリエ
インスティテュート ジーン ゴディノ
インスティテュート ジーン ゴディノ
インスティテュート リジョナル ドゥ キャンサー デ モンペリエ
インスティテュート リジョナル ドゥ キャンサー デ モンペリエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル）, インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）, ユニバーシティ パリ ディドロ−パリ ７, ユニバーシティ パリ ディドロ−パリ ７, ユニヴェルシテ ドゥ モンペリエ, ユニヴェルシテ ドゥ モンペリエ, インスティテュート ジーン ゴディノ, インスティテュート ジーン ゴディノ, インスティテュート リジョナル ドゥ キャンサー デ モンペリエ, インスティテュート リジョナル ドゥ キャンサー デ モンペリエ filed Critical インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル）
Publication of JP2019535306A publication Critical patent/JP2019535306A/ja
Publication of JP2019535306A5 publication Critical patent/JP2019535306A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019542804A 2016-10-25 2017-10-25 Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体 Pending JP2019535306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306392.8 2016-10-25
EP16306392 2016-10-25
PCT/EP2017/077261 WO2018077926A1 (en) 2016-10-25 2017-10-25 Monoclonal antibodies binding to the cd160 transmembrane isoform

Publications (2)

Publication Number Publication Date
JP2019535306A true JP2019535306A (ja) 2019-12-12
JP2019535306A5 JP2019535306A5 (https=) 2020-12-03

Family

ID=57570549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542804A Pending JP2019535306A (ja) 2016-10-25 2017-10-25 Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体

Country Status (9)

Country Link
US (1) US11186635B2 (https=)
EP (1) EP3532502A1 (https=)
JP (1) JP2019535306A (https=)
KR (1) KR20190084264A (https=)
CN (1) CN110121508A (https=)
AU (1) AU2017351764A1 (https=)
BR (1) BR112019008345A8 (https=)
CA (1) CA3080270A1 (https=)
WO (1) WO2018077926A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3812008A1 (en) * 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
WO2023170207A1 (en) * 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
CN116350777A (zh) * 2023-05-17 2023-06-30 中国人民解放军陆军军医大学 麦冬皂苷d自纳米乳在制备肿瘤疫苗佐剂中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
EP1626059A1 (en) 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
JP4658125B2 (ja) 2005-06-28 2011-03-23 パイオニア株式会社 放送受信装置、妨害検出装置および妨害検出方法
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
EP1880729A1 (en) 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of soluble CD160 to suppress immunity
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
EP2006299A1 (en) 2007-06-18 2008-12-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Identification of new isoforms of the MHC-class I specific receptor CD160 and uses thereof
EP2210903A1 (en) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
WO2011116276A2 (en) * 2010-03-18 2011-09-22 Matthew Delisa Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
JP5990511B2 (ja) * 2010-05-28 2016-09-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013072714A1 (en) * 2011-11-15 2013-05-23 Centre National De La Recherche Scientifique (Cnrs) Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
WO2016113351A1 (en) * 2015-01-16 2016-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against orexin receptor type 1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT MOLECULAR MEDICINE, vol. 12(2), JPN7021003241, 2012, pages 188 - 198, ISSN: 0004721871 *
THE JOURNAL OF IMMUNOLOGY, vol. VOL:182, NR:SUPPL. 1, JPN5020000452, April 2009 (2009-04-01), pages 1 - 4, ISSN: 0004721870 *

Also Published As

Publication number Publication date
CA3080270A1 (en) 2018-05-03
US11186635B2 (en) 2021-11-30
WO2018077926A1 (en) 2018-05-03
BR112019008345A8 (pt) 2023-03-07
CN110121508A (zh) 2019-08-13
EP3532502A1 (en) 2019-09-04
AU2017351764A1 (en) 2019-06-06
KR20190084264A (ko) 2019-07-16
BR112019008345A2 (pt) 2019-10-01
US20190256595A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
US11976119B2 (en) Anti-SIRPa antibodies and methods of use thereof
US11186635B2 (en) Monoclonal antibodies binding to the CD160 transmembrane isoform
US11512131B2 (en) Anti-PD-L1 antibody and uses thereof
CN112142847B (zh) 改造的Fc片段，包含其的抗体及其应用
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
JP6847037B2 (ja) 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
US11732044B2 (en) Anti-LAG-3 antibody and use thereof
TW201803905A (zh) 用於免疫腫瘤學之多重專一性抗體
HK1252696A1 (zh) 抗siglec-7抗体及其使用方法
US20240228649A9 (en) Crtam antibodies and methods of treating cancer
WO2019129137A1 (zh) 抗lag-3抗体及其用途
CN114008077A (zh) 抗体和使用方法
US20250179175A1 (en) Anti-cd160 transmembrane isoform antibodies
HK40016537A (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308